Alvotech · NASDAQ (us_market)
· · Luxembourg
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
No qualifying bottom-picking events since 2020.
No scored news yet for a sentiment trend.
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline prod
Alvotech (ALVO) Bank of America Global Healthcare Conference 2026 May 13, 2026 6:40 PM EDTCompany ParticipantsBalaji Prasad - Chief Strategy...
Robert Wessman: Good morning, everyone, and thank you for joining us. The first quarter was focused on three priorities, progressing the FDA resubmission, maintaining a high level of inspection readiness and continuing to expand our commercial business globally, including the launch of three biosimilars across Europe and rest of the world markets. Last week, the FDA began a routine GMP surveillance inspection at our Reykjavik facility, which is currently ongoing.
Robert Wessman: Good morning, everyone, and thank you for joining us. The first quarter was focused on three priorities, progressing the FDA resubmission, maintaining a high level of inspection readiness and continuing to expand our commercial business globally, including the launch of three biosimilars across Europe and rest of the world markets. Last week, the FDA began a routine GMP surveillance inspection at our Reykjavik facility, which is currently ongoing.
Alvotech has reported past first-quarter 2026 earnings, with net income of US$1.03 million compared with US$109.68 million a year earlier, and confirmed the planned departure of long-serving General Counsel Tanya Zharov. The sharp year-on-year swing in net income and a leadership transition in the legal function together raise fresh questions about earnings quality, governance continuity and how the biosimilar pipeline is being supported. Next, we’ll examine how this sharp year-on-year net...
Alvotech has reported past first-quarter 2026 earnings, with net income of US$1.03 million compared with US$109.68 million a year earlier, and confirmed the planned departure of long-serving General Counsel Tanya Zharov. The sharp year-on-year swing in net income and a leadership transition in the legal function together raise fresh questions about earnings quality, governance continuity and how the biosimilar pipeline is being supported. Next, we’ll examine how this sharp year-on-year net...
Alvotech (ALVO) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDTCompany ParticipantsBenedikt Stefansson - Vice President of Investor Relations & Global...
Alvotech (NASDAQ:ALVO) executives said the company’s first-quarter priorities centered on advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercial activity globally as the biosimilar developer works through manufacturing enhancements at its Reykjavik facility. FDA
Alvotech (NASDAQ:ALVO) executives said the company’s first-quarter priorities centered on advancing U.S. regulatory work, maintaining inspection readiness, and expanding commercial activity globally as the biosimilar developer works through manufacturing enhancements at its Reykjavik facility. FDA
Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long‑form earnings release providing additional operational details and business update for Q1 2026 is available at: https://investors.alvotech.com/earnings-calendar under “Q1 2026 Earnings Call”. The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or cons
REYKJAVIK, Iceland, April 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Tanya Zharov, General Counsel, has asked to step down after six years with the Company. “I would like to thank Tanya for her important contribution to the growth of Alvotech over the past six years, preparing the Company for public listings in several jurisdictio
Alvotech overview and recent share performance context Alvotech (NasdaqGM:ALVO) develops and manufactures biosimilar medicines across autoimmune, eye, bone disorder, and cancer indications, and its stock performance has been mixed over different recent periods. The share price was flat over the past day, with a 6.4% decline over the past week. Over the past month the stock shows an 8.7% gain, while the past 3 months reflect a 36.6% decline. Year to date, Alvotech has a 32.4% decline, and the...
Alvotech overview and recent share performance context Alvotech (NasdaqGM:ALVO) develops and manufactures biosimilar medicines across autoimmune, eye, bone disorder, and cancer indications, and its stock performance has been mixed over different recent periods. The share price was flat over the past day, with a 6.4% decline over the past week. Over the past month the stock shows an 8.7% gain, while the past 3 months reflect a 36.6% decline. Year to date, Alvotech has a 32.4% decline, and the...
REYKJAVIK, ICELAND (April 24, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 EST (12:00 GMT, 13:00 BST, 14:00 CEST). To listen to the webca
Alvotech (NASDAQ:ALVO) is one of the best stocks under $5 with huge upside potential. Alvotech (NASDAQ:ALVO) has received several rating updates from analysts since the release of its fiscal Q4 and full-year 2025 results. On March 23, Barclays cut the price target on the stock to $4 from $5 and maintained an Underweight rating on […]
Alvotech (NASDAQ:ALVO) is one of the best stocks under $5 with huge upside potential. Alvotech (NASDAQ:ALVO) has received several rating updates from analysts since the release of its fiscal Q4 and full-year 2025 results. On March 23, Barclays cut the price target on the stock to $4 from $5 and maintained an Underweight rating on […]
Further inthis article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Click for this JNJ update.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 63.2K | $216.78K | 0.00% | Added+146.9% | 2026-03-31 |
| TRowePrice | fundamental | 1.40M | $4.79K | 0.00% | Trimmed-2.6% | 2026-03-31 |